Company intelligence / Profile preview
Duphar Laboratories Ltd.
- Ownership
- Private
- Development stage
- Commercial
Overview
Duphar was a pharmaceutical company with a focus on human and veterinary pharmaceuticals and enzymes. It developed several notable drugs in CNS, cardiovascular, hormone replacement therapy, and gastroenterology before being acquired by Solvay Group in the 1980s–1990s. Its Indian operations underwent multiple mergers/demergers before ultimately becoming part of Abbott via Solvay’s global pharma business sale to Abbott Laboratories in 2009–2010[8]. No current clinical results as an independent entity.
- Therapeutic areas
- GastroenterologyPsychiatryCardiovascularEndocrinology
- Modalities
- Small moleculesenzymesvitamins
- Industry
- Pharma
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Duphar Laboratories Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Duphar Laboratories Ltd..